Intelligent Bio Solutions Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.3M
- Price
- $1.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.63%
- Volume
- 21.1K
About
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Quick stats
Shares outstanding3.3M
Computed float3.1M
Float / shares94.1%
Cash runway (months)5.1
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001725430
Websitehttps://ibs.inc
AI Summary
AI-generated1/21
minorneutralother
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET
Intelligent Bio Solutions (Nasdaq: INBS) will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET, followed by a live Q&A, with a replay available on its investor relations website.
The moderated discussion features President and CEO Harry Simeonidis and VP of Product Development Peter Passaris, covering the company's FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, the supporting clinical data, and the FDA review process.
Management will also address commercial progress outside the United States, where the fingerprint-based drug screening system serves construction, manufacturing, transport and logistics, mining, drug treatment, and coroner customer segments.
Red flags
- FDA 510(k) clearance decision for the lead product remains pending; this event is informational and will not include a regulatory ruling or new data release